Fennec Pharmaceuticals Inc. (FENC)

In August 2025, Fennec reported $9.7 million in total net revenues, a 33% increase year-over-year. In November 2025, the company announced record net product sales of $12.5 million, a 79% year-over-year growth, and its first profitable quarter from operations. Also in November 2025, Fennec announced a proposed public offering of common shares, followed by the pricing and closing of the offering, and the completion of its full debt redemption. In December 2025, positive topline results were announced from a clinical study of PEDMARK® in Japan. In January 2026, Piper Sandler initiated coverage with an "Overweight" recommendation, and the stock price was $7.59 per share, a 16.77% increase from January 31, 2025.

Specific information regarding the demand seasonality for Fennec Pharmaceuticals Inc.'s products was not found. Revenue growth is attributed to expanding adoption in oncology centers and new patient segments, rather than seasonal patterns.

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing therapies to mitigate severe side effects of cancer treatment. Its primary product, PEDMARK®, is approved to reduce the risk of ototoxicity associated with cisplatin chemotherapy in pediatric patients. PEDMARK® received FDA approval in September 2022, while PEDMARQSI received European Commission approval in June 2023 and UK approval in October 2023.

Fennec Pharmaceuticals Inc. operates primarily in the United States, where PEDMARK® was commercially launched in October 2022. PEDMARQSI® is commercially available in the United Kingdom and Germany. The company has an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for commercialization in Europe, the UK, Australia, and New Zealand. An investigator-initiated clinical study of PEDMARK® is being conducted in Japan, with positive topline results announced in December 2025.

Fennec Pharmaceuticals Inc.'s brand reputation is generally positive, driven by the successful commercialization and clinical validation of PEDMARK®/PEDMARQSI®. Regulatory confidence is highlighted by FDA, European Commission, and UK approvals. Positive financial results and topline results from a clinical study in Japan further reinforce the product's efficacy. No specific negative events impacting the company's reputation were found.

Fennec Pharmaceuticals Inc. is primarily controlled by institutional investors. As of January 30, 2026, there were 151 institutional owners and shareholders holding 15,042,742 shares. Major institutional shareholders include Southpoint Capital Advisors LP, Solas Capital Management, LLC, and Rosalind Advisors, Inc. Insider ownership stands at 16.25%, with CFO Robert Andrade directly holding 212,658 common shares.